Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: bioengineering – Page 10

Just like your body has a skeleton, every cell in your body has a skeleton—a cytoskeleton to be precise. This provides cells with mechanical resilience, as well as assisting with cell division. To understand how real cells work, e.g. for drug and disease research, researchers create artificial cells in the laboratory.

However, many artificial cells to date cannot be used to study how cells respond to forces as they don’t have a . TU/e researchers have designed a polymer-based network for artificial cells that mimics a real cytoskeleton, thus making it possible to study with greater accuracy in artificial cells how cells respond to forces.

The research is published in the journal Nature Chemistry.

Read more | >

UC Riverside scientists have developed a nanopore-based tool that could help diagnose illnesses much faster and with greater precision than current tests allow, by capturing signals from individual molecules.

Since the molecules scientists want to detect—generally certain DNA or protein molecules—are roughly one-billionth of a meter wide, the they produce are very small and require specialized detection instruments.

“Right now, you need millions of molecules to detect diseases. We’re showing that it’s possible to get useful data from just a ,” said Kevin Freedman, assistant professor of bioengineering at UCR and lead author of a paper about the tool appearing in Nature Nanotechnology. “This level of sensitivity could make a real difference in disease diagnostics.”

Read more | >

Researchers at the University of Massachusetts Amherst have developed an innovative technology inspired by the synchronization mechanism of WWI fighter aircraft, which coordinated machine gun fire with propeller movement. This breakthrough allows precise, real-time control of the pH in a cell’s environment to influence its behavior. Detailed in Nano Letters, the study opens exciting possibilities for developing new cancer and heart disease therapies and advancing the field of tissue engineering.

“Every cell is responsive to pH,” explains Jinglei Ping, associate professor of mechanical and industrial engineering at UMass Amherst and corresponding author of the study. “The behavior and functions of cells are impacted heavily by pH. Some cells lose viability when the pH has a certain level and for some cells, the pH can change their physiological properties.” Previous work has demonstrated that changes of pH as small as 0.1 pH units can have physiologically significant effects on cells.

Read more | >

A dietary supplement may offer a novel way to enhance the effectiveness of CAR T cell therapy, according to a study conducted by researchers at the Perelman School of Medicine and the Abramson Cancer Center at the University of Pennsylvania. Although this method requires validation through clinical trials, early findings—recently presented during a press briefing at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition—suggest a potentially affordable and accessible strategy to improve CAR T cell functionality and cancer-fighting capabilities.

CAR T cell therapy, first developed at Penn Medicine, is a personalized cancer treatment that reprograms a patient’s immune cells to target and destroy cancer cells.

“Thousands of patients with blood cancers have been successfully treated with CAR T cell therapy, but it still doesn’t work for everyone,” said co-lead author Shan Liu, PhD, a postdoctoral fellow who presented the study at ASH. “We took an outside-the-box approach to improve CAR T cell therapy, by targeting T cells through diet rather than further genetic engineering.”

Read more | >

Middlemen get a bad rap for adding cost and complications to an operation. So, eliminating the go-betweens can reduce expense and simplify a process, increasing efficiency and consumer happiness.

James Dahlman and his research team have been thinking along those same lines for . They’ve created a technique that eliminates noisome middlemen and could lead to new, less-invasive treatments for blood disorders and . It sidesteps the discomfort and risks of current treatments, making life easier for patients.

“This would be an alternative to invasive hematopoietic stem cell therapies—we could just give you an IV drip,” said Dahlman, McCamish Early Career Professor in the Wallace H. Coulter Department of Biomedical Engineering. “It simplifies the process and reduces the risks to patients. That’s why this work is important.”

Read more | >

A research group led by Prof. Yao Baoli and Dr. Xu Xiaohao from Xi’an Institute of Optics and Precision Mechanics (XIOPM) of the Chinese Academy of Sciences have revealed a full-gray optical trap in structured light, which is able to capture nanoparticles but appears at the region where the intensity is neither maximized nor minimized. The study is published in Physical Review A.

The optical trap is one of the greatest findings in optics and photonics. Since the pioneering work by Arthur Ashkin in the 1970s, the has been employed in a broad range of applications in life sciences, physics, and engineering. Akin to its thermal and acoustic counterparts, this trap is typically either bright or dark, located at the field intensity maxima or minima.

In this study, researchers developed a high-order multipole model for gradient forces based on multipole expansion theory. Through immersing the Si particles in the structured light with a petal-shaped field, they found that the high-order multipole gradient forces can trap Si particles at the optical intensity, which is neither maximized nor minimized.

Read more | >

Andrew Cassy had spent his working life in a telecommunications research department until a diagnosis of Parkinson’s disease in 2010 pushed him into early retirement. Curious about his illness, which he came to think of as an engineering problem, he decided to volunteer for clinical trials.

“I had time, something of value that I could give to the process of understanding the disease and finding good treatments,” he says.

In 2024, he was accepted into a radical trial. That October, surgeons in Lund, Sweden, placed neurons that were derived from human embryonic stem (ES) cells into his brain. The hope is that they will eventually replace some of his damaged tissue.

The study is one of more than 100 clinical trials exploring the potential of stem cells to replace or supplement tissues in debilitating or life-threatening diseases, including cancer, diabetes, epilepsy, heart failure and some eye diseases. It’s a different approach from the unapproved therapies peddled by many shady clinics, which use types of stem cell that do not turn into new tissue.

More than 100 clinical trials put stem cells for regenerative medicine to the test. It’s a turning point for a field beset with ethical and political controversy.

Read more | >

Sometimes pain is a necessary warning signal; for example, if we touch something very hot and it burns, we know to move our hand away. But chronic pain can destroy a person’s quality of life, and it can be extremely challenging to get relief. Some researchers have been searching for ways to deactivate pain receptors, so the body no longer feels the neural signals of chronic pain. Using mouse models of acute inflammatory pain, scientists have shown that it is possible to deactivate pain receptors with genetic engineering tools. The work has been reported in Cell.

“What we have developed is potentially a gene therapy approach for chronic pain,” said senior study author Bryan L. Roth, MD, PhD, a distinguished professor at the University of North Carolina (UNC) School of Medicine, among other appointments. “The idea is that we could deliver this chemogenetic tool through a virus to the neurons that sense the pain. Then, you could just take an inert pill and turn those neurons off, and the pain will literally disappear.”

Read more | >

Bioconvergence — Bridging Science And Nature To Shape Tomorrow — Dr. Nina Siragusa Ph.D. — Merck KGaA, Darmstadt, Germany

#NinaSiragusa #MerckGroup #Darmstadt.

Dr. Nina Siragusa, Ph.D., MBA, is the Strategy, Business, and Data & Digital Lead within the global R&D organization of Merck Healthcare KGaA, Darmstadt, Germany. In this role, she leads strategic projects, manages business operations, and drives digital transformation.

Previously, she served as Chief of Staff to Dr. Laura Matz, Chief Science and Technology Officer at Merck KGaA, Darmstadt, Germany. As part of the Science and Technology Office Leadership Team, she was responsible for fostering cross-sectoral collaboration, innovation, and digitalization across Merck’s three business sectors. She also spearheaded the company’s efforts in Bioconvergence, a multidisciplinary approach that synergizes biology, engineering, data, and digitalization. This initiative promises groundbreaking advancements in healthcare and the life sciences, heralding a new era of scientific collaboration for a healthier, more sustainable future.

Prior to that, Dr. Siragusa contributed to corporate innovation in several leadership roles:

Continue reading “Dr. Nina Siragusa — Merck KGaA Darmstadt, Germany — Bridging Science And Nature To Shape Tomorrow” | >